[52Mn]Mn-DOTAGA-Bevacizumab

N/A

Report date: 2025/10/31 17:59:55

Base Information

Drug Name[52Mn]Mn-DOTAGA-Bevacizumab

Drug Alias NameN/A

ClassificationRadiation-emitting products > Nuclides > Manganese > 52MnRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionVascular endothelial growth factor A inhibitors

TargetsVascular endothelial growth factor A

Therapy Area/IndicationsUterine Cervical Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryHungary

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesScanoMed Ltd University Of Debrecen

China Registration ClassN/A

Develop Information

Active CompaniesScanoMed Ltd University Of Debrecen

Inactive CompaniesN/A

Active IndicationsUterine Cervical Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A